{'fraction_non_alphanumeric': 0.04795117698343505, 'fraction_numerical': 0.02964254577157803, 'mean_word_length': 4.627450980392157, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Concurrent chemoradiotherapy with paclitaxel and cisplatin for adenocarcinoma of the cervix.

BACKGROUND
It is unclear whether cisplatin-based concurrent chemoradiotherapy (CCRT) has the same effect on adenocarcinoma as on squamous cell carcinoma.


PATIENTS AND METHODS
We retrospectively analyzed data for 32 patients with stage IIB-IVA cervical adenocarcinoma who were treated with radiotherapy (RT) or CCRT. Fourteen patients were treated with RT, 8 with CCRT using cisplatin alone (CCRT-P), and 10 with CCRT using cisplatin plus paclitaxel (CCRT-TP).


RESULTS
Complete response was achieved in 7/14 patients in the RT group, 4/8 patients in the CCRT-P group, and 9/10 patients in the CCRT-TP group. Ten out of the 14 patients in the RT, 7/8 patients in the CCRT-P, and 2/10 patients in the CCRT-TP groups experienced locoregional recurrence. The 5-year overall survival rate in the RT, CCRT-P, and CCRT-TP groups was 7.1%, 25.0%, and 74.1%, respectively (p=0.0094).


CONCLUSION
The present study demonstrated that CCRT-TP achieved much better local control for adenocarcinoma of the cervix, leading to a decrease in locoregional recurrence.